LINC02700: A Potential Drug Target and Biomarker (G105369436)

Target Name: LINC02700

NCBI ID: G105369436

LINC02700

Other Name(s): LINC02700 variant X4 | long intergenic non-protein coding RNA 2700 | Long intergenic non-protein coding RNA 2700, transcript variant X4

LINC02700: A Potential Drug Target and Biomarker

LINC02700 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell-cell adhesion process, which is critical for various physiological processes, including tissue repair and regeneration. LINC02700 is also involved in cell signaling, and its expression has been associated with various diseases, including cancer.

The discovery of LINC02700 as a potential drug target and biomarker has significant implications for the development of new treatments for various diseases. LINC02700 can be targeted using small molecules or antibodies, which could lead to a more effective and less invasive treatment approach. Additionally, LINC02700 has been shown to have potential as a biomarker for various diseases, which could be used to monitor disease progression and response to treatment.

LINC02700 is a small non-coding RNA molecule that is expressed in various tissues and cells. It is a key regulator of cell-cell adhesion and has been involved in various signaling pathways. LINC02700 is composed of 251 amino acid residues and has a molecular weight of 30.9 kDa. It is expressed in various tissues, including the brain, heart, and pancreas, and has been shown to be involved in various physiological processes, including cell signaling and division.

One of the most significant functions of LINC02700 is its role in cell-cell adhesion. Adhesion is the process by which cells stick together to form tissues and organs. LINC02700 plays a key role in regulating cell-cell adhesion by promoting the interaction between cells and by preventing cell-cell adhesion that could lead to the formation of harmful aggregates.

In addition to its role in cell-cell adhesion, LINC02700 is also involved in various signaling pathways. It has been shown to be involved in the Wnt signaling pathway, which is a critical pathway for cell-cell signaling that plays a role in the development and maintenance of tissues and organs. LINC02700 has also been shown to be involved in the Notch signaling pathway, which is a critical pathway for cell-cell signaling that plays a role in the development and maintenance of tissues and organs.

The association of LINC02700 with various diseases has also led to its potential as a biomarker. LINC02700 has been shown to be involved in the development and progression of cancer, which is a major public health problem. Additionally, LINC02700 has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

The potential drug targets for LINC02700 are vast and varied. One of the most promising potential drug targets for LINC02700 is its role in cell-cell adhesion. Small molecules and antibodies that can block the interaction between LINC02700 and its downstream targets could lead to a more effective treatment approach for various diseases. Additionally, LINC02700's role in cell signaling could be a target for drugs that target signaling pathways and improve therapeutic outcomes.

In conclusion, LINC02700 is a non-coding RNA molecule that has significant implications as a potential drug target and biomarker. Its role in cell-cell adhesion and its involvement in various signaling pathways make it an attractive target for small molecules and antibodies. Further research is needed to fully understand the potential of LINC02700 as a drug target and biomarker, and to develop effective treatments for various diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 2700

The "LINC02700 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02700 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets